AIkido Pharma Offers Status Update On Its Expansion Of Key Patent Applications Into Several Major Ex-US Territories Worldwide

AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided a status update on its expansion of key patent applications into several major ex-US territories worldwide.

For the

AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided a status update on its expansion of key patent applications into several major ex-US territories worldwide.

For the Company's pancreatic cancer drug licensed from The University Texas at Austin, in which the Company currently seeks patent protection in the US, the Company will now also seek protection on the licensed drug formulation in China, India and the European Patent Office, with all member countries designated, which includes all 27 EU member countries plus 11 non-EU countries.

In connection with one of the two patent families relating to antiviral treatments licensed from University of Maryland, Baltimore (UMB), the Company filed a continuing patent application under the Patent Cooperation treaty, which will permit the Company seek patent protection simultaneously in the multitude of worldwide member countries. For the other patent family, the Company filed seeking to expand protection in the European Patent Office, designating all member countries.

Anthony Hayes, CEO of AIkido, stated, "Acquiring solid patent protection is the bedrock of drug asset ownership and essential to acquiring potential future market share in key countries around the world. At the appropriate times and when it makes economic sense, we will continue seeking to expand the territorial patent coverage on our licensed assets."